Aripiprazole
- Generic Name
- Aripiprazole
- Brand Names
- Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27Cl2N3O2
- CAS Number
- 129722-12-9
- Unique Ingredient Identifier
- 82VFR53I78
- Background
Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors. Aripiprazole was given FDA approval on November 15, 2002.
- Indication
Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania. Finally, an extended-release, bimonthly injection formulation of aripiprazole is indicated for the treatment of adult schizophrenia and maintenance therapy for adult bipolar I disorder.
- Associated Conditions
- Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
- Associated Therapies
- Monotherapy
Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 21
- Registration Number
- NCT00802100
- Locations
- 🇺🇸
Medical College of Georgia, Augusta, Georgia, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸SHANTI Clinical Trials, Colton, California, United States
Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 5
- Registration Number
- NCT00746252
- Locations
- 🇺🇸
University of Maryland, School of Medicine, Department of Psychiatry, Division of Child and Adolescent Psychiatry, Baltimore, Maryland, United States
A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2012-09-07
- Lead Sponsor
- Paul Saenger
- Target Recruit Count
- 44
- Registration Number
- NCT00737256
- Locations
- 🇺🇸
Veteran's Affairs Medical Center, Denver, Colorado, United States
Aripiprazole for Methamphetamine Dependence: Double Blind Placebo Trial
- First Posted Date
- 2008-08-05
- Last Posted Date
- 2015-06-26
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00728312
Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia
- First Posted Date
- 2008-07-10
- Last Posted Date
- 2013-11-08
- Target Recruit Count
- 690
- Registration Number
- NCT00712686
Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia
- First Posted Date
- 2008-07-09
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- Kettering Health Network
- Target Recruit Count
- 21
- Registration Number
- NCT00712270
- Locations
- 🇺🇸
Wallace Kettering Neuroscience Institute, Kettering, Ohio, United States
Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder
- Conditions
- Interventions
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2013-07-26
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT00706589
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Inha University Hospital, Inchon, Korea, Republic of
🇰🇷Yonsei University Severance Hospital, Seoul, Korea, Republic of
Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2009-07-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT00689559
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 22
- Registration Number
- NCT00685334
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder
- Conditions
- Interventions
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2013-12-02
- Target Recruit Count
- 493
- Registration Number
- NCT00665366
- Locations
- 🇹🇷
Local Institution, Denizli, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.